Pentadecanoic Acid for Health & Longevity - Quick Reference Sheet

Pentadecanoic Acid for Health & Longevity

Created on 09/27/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Grok 4 – Audit

Pentadecanoic acid, a saturated fat in whole dairy fat, is administered orally in purified form for health and longevity. Higher blood levels line up with a modestly lower chance of heart disease and type 2 diabetes, too mixed with diet to show it is protective. Cholesterol fell further and one liver enzyme fell. Liver fat followed the diet. No serious harms were reported over three months. No shown lifespan effect. (Full Review)

Protocol

200 mg each morning
200 mg
Oral free fatty acid for 12 weeks
300 mg once daily with a meal
300 mg
For 12 weeks, beside an Asian-adapted Mediterranean-style diet
Commercial 100 mg
100 mg daily
Fatty15; below both trial doses and not compared with them
Time to effect
LDL cholesterol
12 weeks
Further drop with 300 mg plus diet than with diet alone
Gamma-glutamyl transferase
12 weeks
Lower versus placebo at 200 mg daily
Hemoglobin
12 weeks
Rise only above a blood-level line, in a later split

Benefits

Contraindications
Key Interactions
  • Statins (cholesterol-lowering drugs; atorvastatin, rosuvastatin): no interaction study (monitor)
  • Omega-3 fatty-acid supplements: no study of additivity or antagonism (monitor)
  • Other prescription and over-the-counter drugs: no studied class interaction at 200 to 300 mg for 12 weeks (monitor)
  • Pregnancy and lactation: fetal exposure unstudied (caution)

Risk & Side Effects

  • High:
  • Medium:
  • Low:
  • Speculative: No controlled data beyond about 12 weeks

Monitoring

Marker Target Why
Circulating pentadecanoic acid No established target; track change from the person's own baseline Shows whether the dose raised the level the trials actually moved
LDL cholesterol <100 mg/dL; <70 mg/dL when artery disease is already a personal priority The one supplement signal that is a validated cardiovascular surrogate
ALT <25 U/L in women; <33 U/L in men Liver-enzyme signal was after-the-fact and only above a blood-level line
AST <30 U/L Second liver enzyme in the same after-the-fact split
GGT <20 U/L The liver enzyme that fell versus placebo at 12 weeks
Hemoglobin Women 12.5–14.5 g/dL; men 14.0–15.5 g/dL An after-the-fact rise was reported above the 5 microgram line
Fasting glucose 75–90 mg/dL Cohorts link the biomarker to diabetes; trials did not move glucose clearly
hs-CRP <1.0 mg/L Cell work is anti-inflammatory; human trials have not shown a CRP drop

Cadence: Baseline before oral use; at 12 weeks, then every 6 to 12 months if use continues. Qualitative markers at baseline and each lab visit.

Qualitative Assessment

  • Energy: ordinary daytime energy, without expecting a stimulant-like change
  • Sleep quality: continuity and feeling restored; trials have not established an effect
  • Gastrointestinal comfort: nausea, loose stools, or fullness after the oral capsule, versus the person's baseline
  • Training tolerance: recovery from usual exercise; no trial has tested an exercise interaction